Ameliorative effect of combined low dose of Pioglitazone and omega-3 on spermatogenesis and steroidogenesis in diabetic rats
| Autor: | Amal M.H. Mackawy, Ebtesam M. Ibrahim, Jehan El‐Gendy, Amal S. El-Shal, Abeer A. Saeed, Mai M. Hasan, Eman M. A. Abdelghany |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Estrogen receptor Peroxisome proliferator-activated receptor Biochemistry Antioxidants Diabetes Mellitus Experimental 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Fatty Acids Omega-3 Testis medicine Animals Hypoglycemic Agents PPAR alpha Testosterone Spermatogenesis Molecular Biology Infertility Male chemistry.chemical_classification biology Dose-Response Relationship Drug Pioglitazone business.industry Glucose transporter Cell Biology medicine.disease Rats Androgen receptor Semen Analysis 030104 developmental biology Endocrinology chemistry Diabetes Mellitus Type 2 030220 oncology & carcinogenesis biology.protein Drug Therapy Combination business GLUT3 medicine.drug |
| Zdroj: | Journal of cellular biochemistryREFERENCES. 121(2) |
| ISSN: | 1097-4644 |
| Popis: | Background Chronic hyperglycemia is linked to either subfertility or infertility among diabetic males. Pioglitazone is one of the thiazolidinediones (TZDs) drugs that are selective peroxisome proliferator-activated receptor (PPAR-γ agonists used for treating type 2 diabetes mellitus (T2DM). Aim This study aims to explore the possible effect of low Pioglitazone dose and omega (ω-3) on rat male reproductive function. Furthermore, we evaluated the add-on effect of combined use of low Pioglitazone dose of and ω-3 on reproductive functions in adult male T2DM rats. Methods Fifty adult male rats were included and subdivided into control and four test subgroups. T2DM was induced in test groups and subdivided into non-treated T2DM, ω-3 treated, 0.6 mg/kg Pioglitazone treated, and combined treated group (orally by gavage). Following 16 weeks, final body weight, testicular weight, fasting plasma glucose, and serum testosterone levels were measured. Semen analysis, testicular testosterone, malondialdehyde (MDA) concentrations, superoxide dismutase (SOD) activity, immunohistochemistry staining for apoptosis marker B-cell lymphoma protein 2 (Bcl-2), proliferation marker as proliferating cell nuclear antigen (PCNA), estrogen receptor α (ERα), androgen receptor (AR) were determined. Caspase-3, nuclear factor-kappa B (NF-kB), glucose transporter 3 (GLUT3), 17β-hydroxysteroid dehydrogenases (17β-HSD) PPARγ, and PPARα genes expression were analyzed by real-time polymerase chain reaction (RT-PCR). Results Our findings revealed that treatment with low dose of Pioglitazone or ω-3 significantly lowered fasting plasma glucose and MDA levels, ameliorated diabetes effects on histological damage, improved antioxidant activity (SOD), significantly improved anti-apoptosis BCL-2 and proliferation (PCNA), remarkably elevated ERα, AR, 17β-HSD PPARγ, and PPARα expression with significant reduction in caspase-3, NF-kB genes expression and improved semen quality as well. Combined use of low dose of and ω-3 has better effects on all measured parameters. Conclusion Small Pioglitazone dose and ω-3 possess beneficial effects on spermatogenic and steroidogenic functions in adult diabetic rat; while combined use of both has an add-on effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text